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1 |  INTRODUCTION
Carbamazepine (CBZ) and its keto- analogue, oxcarbaz-
epine (OXC), are routinely used as antiepileptic drugs 
(AEDs) and are also used in the treatment of chronic pain 
conditions and bipolar disorder. Although effective, their 
use is limited by adverse drug reactions (ADRs), including 
hyponatremia and hypersensitivity. Carbamazepine- and 
oxcarbazepine- induced hyponatremia (COIH) is reported 
in up to half of drug exposures. This is often assumed to be 
asymptomatic but it can lead to difficulties ranging from 
unsteadiness and mild confusion to seizures and coma. 
Careful dose titration and monitoring of sodium levels are 
recommended for reducing the risk of COIH, while indi-
vidual differences in drug metabolism can make titration 
difficult.
HLA-B*1502 is strongly associated with CBZ- induced 
Stevens- Johnson syndrome (SJS) in people of Han Chinese 
ethnicity, increasing the risk about 100- fold.1 In individ-
uals of European descent, HLA-A*3101 is a clinically 
relevant predictor of the full spectrum of CBZ- induced 
hypersensitivity reactions.2,3 To date, no genetic risk fac-
tors have been associated with COIH. Thiazide- induced 
hyponatremia is associated with 2 polymorphisms in the 
KCNJ1 gene, encoding the renal outer medullary potassium 
channel (ROMK), which plays an important role in sodium 
reabsorption along the thick ascending limb of the loop 
of Henle.4 CBZ and OXC seem to influence water reab-
sorption, independent of salt retention, via stimulation of 
the vasopressin 2 receptor/aquaporin (AVPR2) pathway.5 
Mutations in the AVPR2 gene, a regulator of water reab-
sorption, can cause a nephrogenic syndrome of inappro-
priate antidiuresis (NSIAD) with physiologic similarities 
to the inappropriate antidiuresis induced by CBZ and 
OXC.6 Studies of AVPR2 copy number variation, however, 
did not explain variation in sodium levels in non- Hispanic 
Caucasian populations.7
Summary
Objective: To ascertain the clinical and genetic factors contributing to carbamaze-
pine- and oxcarbazepine- induced hyponatremia (COIH), and to carbamazepine 
(CBZ) metabolism, in a retrospectively collected, cross- sectional cohort of people 
with epilepsy.
Methods: We collected data on serum sodium levels and antiepileptic drug levels in 
people with epilepsy attending a tertiary epilepsy center while on treatment with CBZ 
or OXC. We defined hyponatremia as Na+ ≤134 mEq/L. We estimated the CBZ 
metabolic ratio defined as the log transformation of the ratio of metabolite CBZ- diol 
to unchanged drug precursor substrate as measured in serum.
Results: Clinical and genetic data relating to carbamazepine and oxcarbazepine trials 
were collected in 1141 patients. We did not observe any genome- wide significant 
associations with sodium level in a linear trend or hyponatremia as a dichotomous 
trait. Age, sex, number of comedications, phenytoin use, phenobarbital use, and so-
dium valproate use were significant predictors of CBZ metabolic ratio. No genome- 
wide significant associations with CBZ metabolic ratio were found.
Significance: Although we did not detect a genetic predictor of hyponatremia or 
CBZ metabolism in our cohort, our findings suggest that the determinants of CBZ 
metabolism are multifactorial.
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Key Points
• No large, clinically relevant genetic predictors of 
carbamazepine- or oxcarbazepine-induced 
hyponatremia
• Age and concurrent phenytoin, phenobarbital, or 
sodium valproate use was significantly associated 
with carbamazepine metabolic ratio
• No large, clinically relevant genetic predictors of 
carbamazepine metabolic ratio
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We attempted to determine the clinical and genetic fac-
tors contributing to COIH and drug metabolism in a retro-
spectively collected, cross- sectional cohort of people with 
epilepsy of European descent treated with CBZ and OXC, 
which characteristics were previously described.8
2 |  METHODS
2.1 | Study design and phenotypes
We followed a retrospective cohort study design. The ma-
jority of the patients were recruited at a Dutch tertiary epi-
lepsy referral center (SEIN), whereas the remainder were 
recruited around European tertiary referral clinics associ-
ated with the EpiPGX Consortium. Clinical information 
from medical records, with an emphasis on AED history, 
was recorded in an electronic database designed for ret-
rospective pharmacogenomics studies.9 The database was 
used to identify all individuals who were prescribed CBZ 
or OXC and who had a recorded serum sodium level during 
therapy. Most individuals had several measurements, and 
the lowest sodium level recorded was selected for analysis. 
Our primary analyses were structured to test genetic vari-
ants for association with this lowest recorded sodium level 
per subject (mEql/L). Secondary analyses tested for ge-
netic association with the following: (a) COIH (combined 
and per causal drug) and (b) CBZ metabolic ratio. In a sub-
set of CBZ users for which we had concurrently measured 
CBZ- 10,11- diol (CBZ- diol) levels, we calculated the meta-
bolic ratio defined as the log transformation of the ratio 
of metabolite CBZ- diol to unchanged drug precursor sub-
strate as measured in serum. COIH cases were defined as 
having a blood sodium level ≤134 mmol attributed to CBZ 
or OXC as determined by their clinician. COIH controls 
trialed CBZ or OXC for at least 3 months with a sodium 
level ≥135 mmol. Epilepsy- specific cohort demographics 
are presented in Table 1.
2.2 | Sampling and genotype analysis
Serum drug and metabolite concentrations were measured 
during the course of routine monitoring in the morning before 
drug intake. For each sodium level measurement, we recorded 
patient age, serum level of CBZ or OXC, and concomitant 
use of other drugs. Genotyping of all patients was performed 
at deCODE Genetics on Illumina OmniExpress- 12 v1.1 
and OmniExpress- 24 v1.1 single nucleotide polymorphism 
(SNP) arrays. Genotyping quality control was performed as 
described previously.10 Principal components analysis (PCA) 
was performed with European- ancestral samples from the 
HapMap Project to assess cohort substructure and identify 
population outliers (Figure S1). Eigenvectors were computed 
in the genome-wide complex trait analysis tool (GCTA) for 
each subject for inclusion as covariates in genetic- association 
testing.11 Subjects were identified as outliers and removed if 
greater than 3 standard deviations (SD) from the first 8 princi-
pal components. We used the functional mapping and annota-
tion of genome-wide association studies platform (FUMA) to 
generate Manhattan and quantile- quantile (Q- Q) plots.12
2.3 | Study power
We estimated from our recruited sample size that our study 
had 80% power to detect a genetic predictor of relative risk 
Description CBZ OXC Combined
Subjects 1031 297 1252a
% male 51.4% 48.1% 51.2%
Mean age (±SD) 42.9 ± 15.1 38.1 ± 15.9 41.9 ± 15.6
No. AED comedications (max)b 1.0 (5) 0.9 (4) 1.0 (5)
Hyponatremia (Na 
<135 mEq/L)
331 (32%) 170 (57%) 448c
Mean case serum sodium 
(mEq/L)
129.5 ± 4.1 127.5 ± 4.2 129.0 ± 4.2
Mean control serum sodium 
(mEq/L)
139.8 ± 2.5 139.4 ± 2.7 139.7 ± 2.5
Mean serum AED level (mg/L) 
(±SD)b
8.7 ± 2.3 17.8 ± 8.2 —
Metabolic ratio (±SD)d 0.35 ± 0.21 — —
aSeventy- nine subjects trialed both CBZ and OXC. 
bCalculated from SEIN subcohort (n = 1074). 
cFifty- three subjects experienced hyponatremia on both CBZ and OXC. 
dMetabolic ratio calculated on a subset of subjects with serum CBZ- diol level readings (n = 468). 
T A B L E  1  CBZ and OXC cohort 
characteristics
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(approximated to odds ratio) ≥3 with an allele frequency 
≥2% and an alpha level of 1.0 × 10−8, using the power cal-
culator for case-control genetic association analyses PGA.13
2.4 | Statistical analyses
Clinical cofactors influencing sodium levels and COIH in this 
cohort were reported previously and used as covariates in our 
models.8 Association analyses were conducted using additive 
linear or logistic regression models in PLINK, including clin-
ical covariates where appropriate and 8 principal components 
from PCA. Dosage, number of comedications, and AED lev-
els were excluded from the genetic analyses due to missing 
information in the EpiPGX subcohort. We also analyzed the 
significance of clinical variables influencing CBZ metabolic 
ratio using a stepwise linear regression model in SPSS sta-
tistical software. As before, significant clinical cofactors 
from the linear regression model were included as covariates 
along with 8 principal components from PCA. For each as-
sociation test, SNPs with <90% call rate were excluded. The 
threshold for genome- wide statistical significance was set at 
1.0 × 10−8, reflecting an empirical Bonferroni correction for 
5 tests, of the standard 5 × 10−8 genome- wide significance 
threshold.
2.5 | Ethical considerations
All study participants provided written, informed consent for 
genetic analysis. Study protocols were approved by the re-
search ethics committees listed in Table S1.
3 |  RESULTS
We collected clinical and genetic data relating to CBZ 
(n = 1031 subjects) and OXC (n = 297 subjects) trials. A 
subset (n = 79 subjects) were trialed on CBZ and OXC. Of 
the total 1252 patients, 1047 were recruited at SEIN while 
201 were recruited through EpiPGX partner sites. Data on 
drug levels and compliance were available for 98% of the 
SEIN cohort, but not for the EpiPGX partner sites. In 5% 
of our SEIN cohort the drug levels or dosage was below 
therapeutic values (for CBZ <4 mmol/L or <400 mg/d, for 
OXC <10 mmol/L or <900 mg/d). We report 448 cases with 
COIH and 804 controls with normal serum sodium meas-
urement. Within our cases there was a subset of 61 subjects 
with extreme hyponatremia. The incidence of OXC- induced 
hyponatremia (57%) was almost twofold higher than that of 
CBZ (32%). Characteristics of our cohort are described in 
Table 1. A total of 25 subjects were removed after genotyp-
ing quality control.
To test whether common genetic variants predict so-
dium levels, we performed a genome- wide linear regression 
adjusted for age, clobazam use, sex, plus 8 principal com-
ponents. We did not observe any genome- wide significant 
associations with sodium level (Figure 1).
To test whether common genetic variants predict COIH, 
defined as a serum sodium level <135 mEq/L, we per-
formed a case- control genome- wide logistic regression 
adjusted for sex, age <40, plus 8 principal components. 
We did not observe any genome- wide significant associ-
ations when we considered COIH as a dichotomous trait 
(Figure 2). There was a suggestive association signal 
(P < 1 × 10−6) from chromosome 5, in an intergenic region 
approximately 500 Mb downstream of the gene ANKRD55, 
evident in the quantitative and dichotomous analyses of so-
dium. Furthermore, we did not detect evidence for a genetic 
signal in a subset of 61 severe COIH cases, defined as a 
serum sodium ≤125 mEq/L, when compared to controls. 
Neither did we did observe any significant associations 
when we differentiated hyponatremia by causal drug (see 
Figures S2-S4). Given prior reports of an association with 
thiazide- induced hyponatremia, we looked closely within 
the KCNJ1 and AVPR2 genes, yet we did not observe any 
signals of association in our data.
Next, we explored whether clinical cofactors or genetic 
variants could predict the ratio of active drug to metabolite in 
our CBZ- exposed subjects. We modeled the contribution of 
clinical cofactors to CBZ metabolic ratio and found that age, 
sex, number of comedications, phenytoin use, phenobarbital 
F I G U R E  1  Manhattan and Q- Q plots 
of sodium levels (λ = 1.00)
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use, and sodium valproate use were significantly predictive 
of outcome (adjusted r2 = 0.236, Model 5 in Table 2).
To test whether common genetic variants predict CBZ 
metabolic ratio, we then performed a genome- wide linear 
regression adjusted for the covariates in Model 5, plus 8 
principal components. We did not observe any genome- 
wide significant associations with CBZ metabolic ratio 
(Figure 3). The top 10 most significant GWAS markers for 
each analysis are listed in Tables S1-S5. Polymorphisms 
in CYP3A4 and EPHX1 have been shown to associate with 
interindividual variability of CBZ metabolism.14,15 We did 
not observe even nominally significant associations be-
tween SNPs in CYP3A4 and CBZ metabolic ratio. It had 
been reported that homozygous carriers of the EPHX1 
c.416A>G SNP (rs2234922) seemingly show a reduced 
CBZ metabolism, as measured by a significantly de-
creased metabolic ratio.16 We did not replicate this find-
ing (rs2234922; P = 0.303) but we observed a nominally 
significant association between an intronic EPHX1 SNP 
(c.365- 2139T>C) and CBZ metabolic ratio (rs4653689; 
P = 1.1 × 10- 4).
4 |  DISCUSSION
Although we did not detect a genetic predictor of hypona-
tremia in our cohort, we have demonstrated that the determi-
nants of CBZ metabolism are multifactorial. Modeling the 
F I G U R E  2  Manhattan and Q- Q plots 
of COIH (λ = 1.00)
F I G U R E  3  Manhattan and Q- Q plots 
of carbamazepine metabolic ratio (λ = 0.98)
Model Factors R R2 Adjusted R2 Std. error
1 PHT .363a 0.132 0.130 0.196
2 PHT, NoCoMed .421b 0.177 0.174 0.191
3 PHT, NoCoMed, 
age
.458c 0.210 0.205 0.188
4 PHT, NoCoMed, 
age, PHB
.486d 0.236 0.230 0.185
5 PHT, NoCoMed, 
age, PHB, VPA
.493e 0.243 0.236 0.184
NoCoMed, number of comedications; PHB, phenobarbital; PHT, phenytoin; VPA, sodium valproate.
T A B L E  2  Stepwise linear regression 
of carbamazepine metabolic ratio
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contribution of clinical variables showed there were strong 
nongenetic predictors of CBZ metabolism. Subject age, total 
number of comedications, and the concurrent use of pheny-
toin, phenobarbital, or sodium valproate were significantly 
associated with a higher CBZ- diol to CBZ ratio. Much of 
this can be explained by the induction of the cytochrome 
P450 enzyme CYP3A4. CBZ is metabolized in the liver by 
CYP3A4 to carbamazepine- 10,11- epoxide, which is further 
metabolized by microsomal epoxide hydrolase (mEH) to 
carbamazepine- 10,11- diol.17 Phenytoin and phenobarbital 
induce CYP3A4 and thus can lower plasma CBZ levels but 
leave the metabolite levels unaltered, which results in the ob-
served higher metabolic ratio.18,19 Sodium valproate inhibits 
epoxide hydrolase, potentiating higher levels of the active 
metabolite CBZ- 10,11- epoxide, which is associated with 
toxicity and adverse events,20 but this was not directly meas-
ured in this study. Valproate has been shown to increase dose 
ratios between CBZ and its metabolites, for both the diol and 
epoxide forms.21 Age has been found previously to contrib-
ute to pharmacokinetic variability in individuals using CBZ 
with increasing clearance until age 33 and a gradual decrease 
toward older age.22
A limitation of the study is that AED dosage was not 
reliably recorded in our cohort and we had to make an as-
sumption that the measurement of CBZ metabolic ratio 
was independent of the individual subject's dosage. In the 
subset of subjects for whom serum CBZ- diol and CBZ dos-
age information was available (n = 40) we did not detect 
a significant effect of CBZ dose on the metabolic ratio 
(P = 0.41).
CBZ and OXC are widely prescribed but their use co-
incides with a high prevalence of COIH. Within our cohort 
OXC- induced hyponatremia has a much higher prevalence 
than that of CBZ, which is consistent with previous esti-
mates.23,24 From clinical experience, susceptibility to COIH 
is individually variable. Experimental studies and a recent 
clinical report suggest that COIH is caused by a direct effect 
of CBZ/OXC on the kidney by stimulating the vasopressin 
receptor.25,26 Mutations in the V2R/AQP2 pathway regulat-
ing water reabsorption can cause disorders clinically similar 
to the syndromes of inappropriate secretion of antidiuresis 
associated with CBZ/OXC use. Meanwhile thiazide- induced 
hyponatremia has been associated with polymorphisms in the 
gene KCNJ1 and a suggestive association with a variant in 
SLCO2A1, encoding a prostaglandin transporter; these sig-
nals did not show even nominal significance in our data.4,27 
We further looked for an effect from these markers within the 
subset of 53 subjects who experienced hyponatremia on both 
CBZ and OXC independently, but there was no significant 
enrichment.
Previously described clinical predictors of serum so-
dium levels explain only 11%- 14% of the variance in the 
SEIN cohort.8 Therefore, it is hypothesized that genetic 
variation could in part explain the variation in susceptibil-
ity to COIH. Yet, after analyzing sodium levels in a linear 
trend and hyponatremia as a dichotomous trait, we did not 
find genetic predictors for COIH. A recent report of vari-
ants in NFAT5 and SLC4A10 with suggestive association 
with plasma osmolality further imply a genetic component 
to hyponatremia, but these variants showed no evidence 
for effect on serum sodium measurements in our study, 
albeit we were not as powered as the original discovery 
cohort.28
In summary, our study rules out common genetic vari-
ants of clinically relevant effect size; however, genetic sus-
ceptibility for COIH cannot be ruled out completely, as rare 
variants and combinations of genetic variants of smaller 
effect size (polygenic risk) may contribute to overall risk. 
Further study, ideally in a prospective cohort with baseline 
sodium level and CBZ- diol measurements, is warranted 
to investigate the genetic contribution to CBZ- and OXC- 
induced hyponatremia.
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